LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

1.98

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.94

Максимум

1.98

Ключови измерители
By Trading Economics
Приходи	53M 17M
Продажби	51M 73M
Марж на печалбата	23.095
Служители	341
EBITDA	55M 22M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+101.01% upside

Дивиденти
By Dow Jones
Следващи печалби	19.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	20M 111M
Предишно отваряне	1.98
Предишно затваряне	1.98

Настроения в новините

By Acuity

50%

154 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

1.47 / 1.64 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.03.2026 г., 23:35 ч. UTC

Значими събития в новините

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Значими събития в новините

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1.03.2026 г., 23:39 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

1.03.2026 г., 23:39 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1.03.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1.03.2026 г., 23:24 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

1.03.2026 г., 23:24 ч. UTC

Пазарно говорене

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1.03.2026 г., 23:21 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.03.2026 г., 23:21 ч. UTC

Пазарно говорене

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1.03.2026 г., 23:19 ч. UTC

Значими събития в новините

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1.03.2026 г., 23:17 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1.03.2026 г., 23:14 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1.03.2026 г., 22:55 ч. UTC

Значими събития в новините

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1.03.2026 г., 22:54 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1.03.2026 г., 22:53 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1.03.2026 г., 22:38 ч. UTC

Пазарно говорене

Значими събития в новините

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1.03.2026 г., 22:21 ч. UTC

Печалби

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1.03.2026 г., 22:17 ч. UTC

Пазарно говорене

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1.03.2026 г., 22:13 ч. UTC

Пазарно говорене

Значими събития в новините

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1.03.2026 г., 21:40 ч. UTC

Пазарно говорене

Значими събития в новините

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1.03.2026 г., 21:35 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1.03.2026 г., 21:30 ч. UTC

Пазарно говорене

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1.03.2026 г., 21:27 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1.03.2026 г., 21:19 ч. UTC

Пазарно говорене

Значими събития в новините

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1.03.2026 г., 20:58 ч. UTC

Пазарно говорене

Значими събития в новините

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1.03.2026 г., 20:40 ч. UTC

Пазарно говорене

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1.03.2026 г., 20:24 ч. UTC

Пазарно говорене

Значими събития в новините

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

101.01% нагоре

12-месечна прогноза

Среден 4 USD 101.01%

Висок 4 USD

Нисък 4 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

154 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.